AL-101 is under clinical development by Alector and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-101 is under development for the treatment of neurological disorders like frontotemporal dementia, Alzheimer’s disease and Parkinson’s disease. The drug candidate is recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z, a)] kappa monoclonal antibody. It acts by targeting sortilin1 (SORT1) receptor. It is administered through intravenous and subcutaneous route.
Alector is a biotechnology company that develops therapies for immune system to cure neurodegeneration and cancer. The company discovers and develops immune-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. It combines state-of-the-art antibody technology and recent discoveries in neuroimmunology and oncology to fight cancer. Alector also generates and validates antibody drugs that engage key disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. Alector is headquartered in South San Francisco, California, the US.
For a complete picture of AL-101’s drug-specific PTSR and LoA scores, buy the report here.